Joosten Michiel H M A, de Bree Remco, Van Cann Ellen M
Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Oral Oncol. 2017 Mar;66:87-92. doi: 10.1016/j.oraloncology.2016.12.027. Epub 2017 Jan 21.
The management of the clinically node negative (N0) neck in patients with squamous cell carcinoma of the maxilla (MSCC) is a matter of debate. In this retrospective cohort study the incidence of occult metastases is determined in clinically N0 MSCCs, as well as histopathological factors associated with occult metastases.
95 patients with clinically N0 MSCCs had maxillectomy. 18 patients with elective treatment of the neck were excluded. The remaining 77 patients followed a 'watch and wait' strategy for the neck and were included in this study. The incidence of occult metastases was calculated and Cox regression analysis was used to assess the predictive and prognostic value of clinical and histopathological parameters.
Occult metastases occurred in 14.3% (11/77) in the whole cohort and in 19.0% (11/58) in T2-T4 clinically N0 MSCC. Patients with T4 clinically N0 MSCC, showed the highest rate of occult metastases (24.1%). 45.5% of the occult metastases developed in the contralateral neck. The hazard ratio to develop occult metastasis was 5.39 (p=0.017) for perineural growth and 11.12 (p=0.003) for perivascular invasion. Salvage for cervical recurrence was poor at 40%.
We recommend elective treatment of the neck or improved diagnostics to detect occult metastases in T2-T4 clinically N0 MSCC or when the biopsy specimen shows perineural growth or perivascular invasion. Since the contralateral neck was involved in 45.5% of the regional recurrences, we emphasize the importance of bilateral neck management. Improved diagnostics, like sentinel node biopsy, could possibly further reduce occult metastatic disease.
上颌鳞状细胞癌(MSCC)患者临床颈部淋巴结阴性(N0)的处理存在争议。在这项回顾性队列研究中,确定临床N0的MSCC隐匿性转移的发生率以及与隐匿性转移相关的组织病理学因素。
95例临床N0的MSCC患者接受了上颌骨切除术。18例接受颈部选择性治疗的患者被排除。其余77例患者对颈部采取“观察等待”策略并纳入本研究。计算隐匿性转移的发生率,并采用Cox回归分析评估临床和组织病理学参数的预测及预后价值。
整个队列中隐匿性转移发生率为14.3%(11/77),临床N0的T2 - T4期MSCC中为19.0%(11/58)。临床N0的T4期MSCC患者隐匿性转移发生率最高(24.1%)。45.5%的隐匿性转移发生在对侧颈部。神经周围生长发生隐匿性转移的风险比为5.39(p = 0.017),血管周围侵犯为11.12(p = 0.003)。颈部复发的挽救治疗效果较差,为40%。
我们建议对临床N0的T2 - T4期MSCC或活检标本显示神经周围生长或血管周围侵犯时,进行颈部选择性治疗或改进诊断方法以检测隐匿性转移。由于45.5%的区域复发累及对侧颈部,我们强调双侧颈部处理的重要性。像前哨淋巴结活检这样的改进诊断方法可能进一步减少隐匿性转移疾病。